Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 6,436 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin to Skin Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

Study to Examine the Benefits of Fabric Made With Lyocell/Chitosan/Ceramide in the Treatment of Children With Mild to Moderate Eczema

NCT02224950
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Non-medicated Emollient plus Lyocell/Chitosan Sleeve, Non-medicated Emollient plus Cotton Sleeve, Placebo Sleeve
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
3 Months to 5 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 26, 2026, 11:10 PM EDT
Completed Phase 1 Interventional

Biological Therapy in Treating Patients With Metastatic Melanoma

NCT00045357
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
therapeutic autologous lymphocytes
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 26, 2026, 11:10 PM EDT
Active, not recruiting Phase 3 Interventional

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
216
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 11:10 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Tele-Exercise Platform for Plantar Wound Healing

NCT06439667
View directory record Official record
Conditions
Diabetic Foot Ulcer, Wound Healing, Wound Care
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 26, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

NCT04571567
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab
Drug
Lead sponsor
Saakshi Khattri
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 26, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

NCT03606967
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Orange, California • Sacramento, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 11:10 PM EDT
Not yet recruiting Not applicable Interventional

Implementing a Digital Alcohol Intervention to Raise Women's Awareness of Alcohol-related Breast Cancer Risk During Routine Screening Visits

NCT07799467
View directory record Official record
Conditions
Breast Cancer, Alcohol Drinking
Interventions
Sobriety Digital Intervention
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
40 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 26, 2026, 11:10 PM EDT
Not listed Not applicable Interventional

Use of Epidermal Expansion System for Epidermal Grafting on Hypopigmented Skin and Surgical Wounds

NCT01590329
View directory record Official record
Conditions
Surgical Wound, Hypo-pigmented Skin
Interventions
Momelan Technologies Epidermal Graft Harvesting System
Device
Lead sponsor
Momelan Technologies
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 26, 2026, 11:10 PM EDT
Completed Not applicable Interventional

Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions

NCT00471601
View directory record Official record
Conditions
Breast Cancer
Interventions
counseling intervention, questionnaire administration, psychosocial assessment and care, quality-of-life assessment
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 26, 2026, 11:10 PM EDT
Withdrawn Not applicable Interventional

Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

NCT02470819
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Tumor, Advanced Gynecologic Cancer
Interventions
Genetic profiling
Genetic
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 26, 2026, 11:10 PM EDT
Recruiting Not applicable Interventional

IMPACT Trial: Intervention to iMProve AdherenCe Equitably

NCT05496829
View directory record Official record
Conditions
Breast Cancer
Interventions
Multicomponent Adherence Intervention, Usual Care
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 26, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT07037901
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Interventions
IMG-007, Placebo
Drug
Lead sponsor
Inmagene LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Lancaster, California • Los Angeles, California • Ocala, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 26, 2026, 11:10 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

NCT00034281
View directory record Official record
Conditions
Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm, Renal Neoplasm
Interventions
TAK-165
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
4
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 26, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Patient Reminder and Self-Referral Via Online Patient Portals and Text Messaging to Improve Adherence to Breast Cancer Screening

NCT05526872
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Best Practice, Health Education, Interview, Planned Notification, Survey Administration
Other · Behavioral
Lead sponsor
Emory University
Other
Eligibility
50 Years to 74 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 26, 2026, 11:10 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis

NCT02193139
View directory record Official record
Conditions
Hyperhidrosis
Interventions
WL8713, 6 mg, WL8713, 12 mg, WL8713, 18 mg, WL8713, 24 mg, Placebo
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 26, 2026, 11:10 PM EDT
Terminated Not applicable Interventional

Comparison of Elective Lymph Node Treatment Versus Clinical Observation in the Absence of Palpable Lymph Nodes for High Risk Skin Squamous Cell Carcinoma (SCC)

NCT01252329
View directory record Official record
Conditions
High Risk Cutaneous Squamous Cell Carcinoma
Interventions
elective lymph node dissection
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 26, 2026, 11:10 PM EDT
Completed Phase 3 Interventional

Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis

NCT00692172
View directory record Official record
Conditions
Psoriasis
Interventions
Alefacept
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
19
States / cities
Hot Springs, Arkansas • Fresno, California • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 26, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study in Participants With Moderate to Severe Psoriasis

NCT01474512
View directory record Official record
Conditions
Psoriasis
Interventions
80 mg Ixekizumab Dosing Regimens 1, 2, and 3, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 26, 2026, 11:10 PM EDT
Completed Not applicable Interventional

iMETX (Individualized Metabolic RX): a Pilot Study

NCT03158519
View directory record Official record
Conditions
Breast Cancer
Interventions
iMETX intervention
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 26, 2026, 11:10 PM EDT
Active, not recruiting No phase listed Observational

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

NCT03281902
View directory record Official record
Conditions
Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 26, 2026, 11:10 PM EDT
Completed Not applicable Interventional

A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer

NCT05408260
View directory record Official record
Conditions
Malignant Breast Neoplasm
Interventions
Ultrasonography, Automated Breast Ultrasound
Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 26, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Lycomato on Skin Attributes in Healthy Participants.

NCT05328388
View directory record Official record
Conditions
Skin
Interventions
Lycomato
Dietary Supplement
Lead sponsor
LycoRed Ltd.
Industry
Eligibility
35 Years to 55 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 26, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

NCT02603146
View directory record Official record
Conditions
Healthy Participants, Rheumatoid Arthritis (RA) Prevention
Interventions
Hydroxychloroquine, HCQ Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 26, 2026, 11:10 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 26, 2026, 11:10 PM EDT